Literature DB >> 9420064

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.

S C Piscitelli1, W D Figg, B Hahn, G Kelly, S Thomas, R E Walker.   

Abstract

The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9420064      PMCID： PMC164214     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review.

Authors:  S C Ball; K A Sepkowitz; J L Jacobs
Journal:  Am J Gastroenterol       Date:  1997-01       Impact factor: 10.864

2.  Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.

Authors:  T L Chen; G B Vogelsang; B G Petty; R B Brundrett; D A Noe; G W Santos; O M Colvin
Journal:  Drug Metab Dispos       Date:  1989 Jul-Aug       Impact factor: 3.922

3.  Stability of thalidomide in human plasma.

Authors:  R Huupponen; K Pyykkö
Journal:  Clin Chem       Date:  1995-08       Impact factor: 8.327

4.  In vitro activity of thalidomide against Mycobacterium avium complex.

Authors:  T Vicente; A Ortega; P Muñoz; M D Diaz; E Bouza
Journal:  Arch Intern Med       Date:  1993-02-22

5.  The treatment of microsporidial diarrhoea with thalidomide.

Authors:  D Sharpstone; A Rowbottom; M Nelson; B Gazzard
Journal:  AIDS       Date:  1995-06       Impact factor: 4.177

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Thalidomide treatment for chronic graft-versus-host disease.

Authors:  D Heney; D R Norfolk; J Wheeldon; C C Bailey; I J Lewis; D L Barnard
Journal:  Br J Haematol       Date:  1991-05       Impact factor: 6.998

8.  Pentoxifylline suppression of tumor necrosis factor gene transcription.

Authors:  G M Doherty; J C Jensen; H R Alexander; C M Buresh; J A Norton
Journal:  Surgery       Date:  1991-08       Impact factor: 3.982

9.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Authors:  E P Sampaio; E N Sarno; R Galilly; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

10.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Authors:  A L Moreira; E P Sampaio; A Zmuidzinas; P Frindt; K A Smith; G Kaplan
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307
View more
  8 in total

1.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

2.  Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

Authors:  Jodi A Muscal; Yongkai Sun; Jed G Nuchtern; Robert C Dauser; Leticia H McGuffey; Brian W Gibson; Stacey L Berg
Journal:  Cancer Chemother Pharmacol       Date:  2011-11-23       Impact factor: 3.333

Review 3.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.

Authors:  Evangelos J Giamarellos-Bourboulis; Helen Poulaki; Nikolaos Kostomitsopoulos; Ismene Dontas; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

6.  Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.

Authors:  F L Khanim; B A M E Merrick; H V Giles; M Jankute; J B Jackson; L J Giles; J Birtwistle; C M Bunce; M T Drayson
Journal:  Blood Cancer J       Date:  2011-10-21       Impact factor: 11.037

7.  Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies.

Authors:  Shakir Adeyinka Atoyebi; Rajith K R Rajoli; Ebunoluwa Adejuyigbe; Andrew Owen; Oluseye Bolaji; Marco Siccardi; Adeniyi Olagunju
Journal:  Eur J Pharm Sci       Date:  2019-09-10       Impact factor: 4.384

Review 8.  Clinical pharmacokinetics of thalidomide.

Authors:  Steve K Teo; Wayne A Colburn; William G Tracewell; Karin A Kook; David I Stirling; Markian S Jaworsky; Michael A Scheffler; Steve D Thomas; Oscar L Laskin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 5.577
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.